

 ALLIANCE HEALTHCARE SERVICES

100 Bayview Circle, Suite 400
Newport Beach, CA 92660
P 800.544.3215 F 949.242.5397
www.alliancehealthcareservices-us.com

Br. 1

January 29, 2013

Nuclear Regulatory Commission
Region I
475 Allendale Road
King of Prussia, PA 19406

License Number: 47-25570-01
Docket Number: 03035774

Dear Sir/Madam:


Please amend our license to add the following physicians as Authorized Users.

<u>Authorized User</u>	<u>Material and Use</u>
Robert L. Bridges, MD	35.200
Marc R. Beck, MD	35.200

The Nuclear Regulatory Commission license that lists the named doctors as Authorized Users is attached.

If you have any further questions please do not hesitate to contact me.

Sincerely,



Michael Culley MS CNMT
Corporate Radiation Safety Officer
Alliance HealthCare Services, Inc.
978-852-3527
Email: mculley@allianceimaging.com

REC RG 1 02 04 13 PM 07:11

579933

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated June 3, 2010
1. Diagnostic Health Center of Anchorage, LLC. a wholly subsidiary of Alliance HealthCare Services	3. License number 50-23214-01 is amended in its entirety to read as follows:
2. 4100 Lake Otis Parkway #102 Anchorage, Alaska 99508	4. Expiration date November 30, 2014
	5. Docket No. 030-20372 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Iodine-131 permitted by 10 CFR 35.300	C. Sodium iodide Iodine-131 in capsule form	C. 300 millicuries
D. Any byproduct material permitted by 10 CFR 31.11	D. Prepackaged kits	D. 50 millicuries

9. Authorized use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
 - B. Any imaging and localization study permitted by 10 CFR 35.200.
 - C. Any Iodine-131 procedure permitted by 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.75.
 - D. In-vitro studies.

CONDITIONS

- 10. Licensed material may be used only at the licensee's facilities located at Lake Otis Medical Plaza, 4100 Lake Otis Parkway #102, Anchorage, Alaska.
- 11. The Radiation Safety Officer for this license is Robert L. Bridges, M.D.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
50-23214-01

Docket or Reference Number
030-20372

Amendment No. 19

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use:

<u>Authorized Users</u>	<u>Material and Use</u>
Sean Bryant, M.D.	35.100; 35.200; 31.11
Jennifer L. Kemp, M.D.	35.100; 35.200; 31.11
Brian Steele, M.D.	35.100; 35.200; 31.11
Lawrence L. Emmons, M.D.	35.100; 35.200; oral administration of sodium iodide I-131; 31.11
Robert L. Bridges, M.D.	35.100; 35.200; oral administration of sodium iodide I-131; 31.11
Molly B. Southworth, M.D.	Oral administration of sodium iodide I-131
Marc R. Beck, M.D.	35.100; 35.200; oral administration of sodium iodide I-131; 31.11

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
50-23214-01Docket or Reference Number
030-20372

Amendment No. 19

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated January 21, 2003 (ML022480211)
- B. Letter dated February 18, 2003 (ML030300297)
- C. Letter dated October 06, 2003 (ML033160636)
- D. Letter dated October 27, 2003 (ML033160636)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: September 16, 2010By: Lizette Roldan-Otero

Lizette Roldan-Otero, Ph.D., Health Physicist
Nuclear Materials Safety Branch B
Region IV
Arlington, Texas 76011-4125

This is to acknowledge the receipt of your letter/application dated

11/29/13, and to inform you that the initial processing which includes an administrative review has been performed.

Amendment (47-25570-01)
There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 579933.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.